NO-donating aspirin; anti-inflammatory. Blocks inflammatory mediator production in isolated human monocytes (IC50 values are 0.07, 0.13, 0.15 and 0.18 μM for IL-1β, PGE2, IL-10 and TNF-α respectively). Decreases COX-2 expression (IC50 = 0.13 μM); disrupts proteasome-mediated degradation of iκB-α. Antiproliferative in HCT116 colon cancer cells; sensitizes drug-resistant ovarian tumor cells to cisplatin (Cat. No. 2251).
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 331.28. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.02 mL||15.09 mL||30.19 mL|
|5 mM||0.6 mL||3.02 mL||6.04 mL|
|10 mM||0.3 mL||1.51 mL||3.02 mL|
|50 mM||0.06 mL||0.3 mL||0.6 mL|
References are publications that support the biological activity of the product.
Ricciotti et al (2010) NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes. J.Immunol. 184 2140 PMID: 20065114
Yamakawa et al (2008) Growth inhibition of human colon cancer cell line HCT116 by bis[2-(acylamino)phenyl] disulfide and its action mechanism. Biol.Pharm.Bull. 31 916 PMID: 18451518
Bratasz et al (2008) NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. J.Transl.Med. 6 9 PMID: 18302761
Gao et al (2008) Immunomodulatory activity of synthetic triterpenoids: inhibition of lymphocyte proliferation, cell-mediated cytotoxicity, and cytokine gene expression through suppression of NF-κB. Immunopharmacol.Immunotoxicol. 30 581 PMID: 18608528
If you know of a relevant reference for NCX 4040, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: NCX 4040, NCX 4040 supplier, NCX4040, NO, nitric, oxide, donating, donors, aspirin, para, cyclooxygenase, inhibitors, inhibits, anti-inflammatory, inflammation, NSAIDs, antitumor, cisplatin, resistant, Cyclooxygenase, Donors, /, Precursors, 4531, Tocris Bioscience
Citations for NCX 4040
Citations are publications that use Tocris products.
Currently there are no citations for NCX 4040. Do you know of a great paper that uses NCX 4040 from Tocris? Please let us know.
Reviews for NCX 4040
There are currently no reviews for this product. Be the first to review NCX 4040 and earn rewards!
Have you used NCX 4040?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.